Serum levels of fibroblast growth factor 23 (FGF23), a potent phosphaturic hormone, are
increased in patients with CKD due to a homeostatic response to restore serum phosphate …

Over the last two decades, scientific developments have enhanced our understanding of the
pathogenesis of cardiovascular disease in patients with CKD, and specific nontraditional risk …

CKD associates with phosphate retention, contributing to an increased risk of secondary
hyperparathyroidism, vascular calcification, and cardiovascular mortality …

Background Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be
modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported …

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates phosphorus
balance by enhancing urinary phosphorus excretion and inhibiting the synthesis of 1, 25 …

Abstract Fibroblast growth factor-23 (FGF23) induces phosphaturia through its effects on
renal tubules. Higher levels of FGF23 associate with cardiovascular disease (CVD) events …

Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …

Genetic causes of abnormal urinary phosphate losses are either due to primary tubular
defects altering sodiumcoupled phosphate transport in the proximal tubule, or, more …

In advanced renal disease the kidney is unable to maintain neutral phosphate balance due
to decreased urinary excretion. Hyperphosphatemia is a major risk factor for death …

Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …